drugset / Trial / NCT04426968
A Phase II Study of Hepalatide in Subjects With Chronic Hepatitis B
RandomizedParallel-groupQuadruple-blindTreatment
Summary
A Phase II Randomized, Double-blind, Placebo-controlled, Multi-center, Dose-effect Relationship Study of Hepalatide for Injection Combined with Pegylated Interferon in Subjects with Chronic Hepatitis B
Timeline
- Start
- 2021-06-18
- Primary completion
- 2023-11-01
- Completion
- 2023-11-29
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Hepalatide | Protein / enzyme biologic | 2.1 mg | Subcutaneous |
| Subject | Hepalatide | Protein / enzyme biologic | 4.2 mg | Subcutaneous |
| Subject | Hepalatide | Protein / enzyme biologic | 6.3 mg | Subcutaneous |
| Background | Peginterferon alfa-2a | Protein / enzyme biologic | 180 ug | Subcutaneous |